TY - JOUR
T1 - Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis
AU - Matsumoto, Kotaro
AU - Suzuki, Katsuya
AU - Yoshida, Hiroto
AU - Magi, Mayu
AU - Kaneko, Yuko
AU - Takeuchi, Tsutomu
N1 - Funding Information:
KM and KS declare no conflicts of interest. HY and MM were employees of Chugai Pharmaceutical Co., Ltd. TT and KY received research grants from Chugai Pharmaceutical Co., Ltd.
Funding Information:
We are grateful to support from Chugai Pharmaceutical Co. Ltd. , Keio University School of Medicine , and JSPS KAKENHI (grant number JP21K16306 ).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/10
Y1 - 2022/10
N2 - Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are two types of primary large vessel vasculitis (LVV). LVV is an intractable, rare disease with a high relapse rate. Disease progression in asymptomatic patients is an important issue in the clinical management of LVV. Useful biomarkers associated with clinical phenotypes, disease activity, and prognosis may be present in peripheral blood. In this review, we focused on peripheral leukocyte counts, surface markers, functions, and gene expression in LVV patients. In particular, we explored longitudinal changes in circulating immune cell phenotypes during the active phase of the disease and during treatment. The numbers and phenotypes of leukocytes in the peripheral blood were different between LVV and healthy controls, GCA and TAK, LVV in active versus treatment phases, and LVV in treatment responders versus non-responders. Therefore, biomarkers obtained from peripheral blood immune cells may be useful for longitudinal monitoring of disease activity in LVV.
AB - Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are two types of primary large vessel vasculitis (LVV). LVV is an intractable, rare disease with a high relapse rate. Disease progression in asymptomatic patients is an important issue in the clinical management of LVV. Useful biomarkers associated with clinical phenotypes, disease activity, and prognosis may be present in peripheral blood. In this review, we focused on peripheral leukocyte counts, surface markers, functions, and gene expression in LVV patients. In particular, we explored longitudinal changes in circulating immune cell phenotypes during the active phase of the disease and during treatment. The numbers and phenotypes of leukocytes in the peripheral blood were different between LVV and healthy controls, GCA and TAK, LVV in active versus treatment phases, and LVV in treatment responders versus non-responders. Therefore, biomarkers obtained from peripheral blood immune cells may be useful for longitudinal monitoring of disease activity in LVV.
KW - Gene expression
KW - Giant cell arteritis
KW - Immuno-phenotyping
KW - Takayasu arteritis
KW - Vasculitis
UR - http://www.scopus.com/inward/record.url?scp=85135505869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135505869&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2022.103160
DO - 10.1016/j.autrev.2022.103160
M3 - Review article
C2 - 35926769
AN - SCOPUS:85135505869
VL - 21
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 10
M1 - 103160
ER -